10X Genomics

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

10X Genomics reports solid earnings, eyes growth through innovation

10X Genomics delivered solid earnings in Q4 2022, with revenue growth and strong product innovation driving market presence and customer engagement.
Despite challenges like operational constraints and margin expectations, the company focuses on financial sustainability and market adaptability for future growth.
Opportunities lie in new sample types exploration, product success with Xenium and Visium HD, and customer response to Chromium Flex, indicating potential for revenue growth and market expansion.
Balanced guidance discussions and a focus on key products position 10X Genomics for strategic growth in 2023, with a global market outlook and emphasis on innovation and customer satisfaction.

10x Genomics reports robust Q1 revenue growth, eyes operational efficiency

10x Genomics delivered strong revenue growth in Q1 2023, driven by spatial portfolio and Chromium consumables, with raised revenue guidance for the year.
The company faces challenges in China and margin pressures but sees opportunities in product enhancements, market expansion, and revenue diversification.
Overall, 10x Genomics is strategically positioned for growth, with a focus on operational efficiency, customer adoption, and revenue optimization.

10X Genomics reports robust Q2 growth amidst China challenges

10X Genomics saw strong revenue growth in Q2 2023, driven by single cell and spatial portfolios.
While facing challenges in China, opportunities lie in expanding applications and clinical adoption.
Operational improvements and product advancements position the company for future growth.
Focus on margin improvement and revenue diversification key for sustained success.

10x Genomics reports robust Q3 revenue growth and strategic realignment

10x Genomics showcased strong revenue growth driven by Xenium's success, with plans to enhance product offerings and rebalance resources for future growth.
Despite challenges in gross margin and flat Chromium revenue, the company remains optimistic about its outlook and growth potential in spatial placements.
Opportunities lie in leveraging Xenium's capabilities, driving consumable revenue through discounts, and focusing on the Chromium franchise for sustained growth.

10x Genomics reports strong Q4 earnings, eyes growth opportunities

10x Genomics anticipates revenue of $670-690 million for 2024.
Guidance philosophy balances upsides and downsides for growth.
Strategic focus on product portfolio and long-term gross margin profile.
Emphasis on investments for future growth and maintaining innovation.

10x Genomics reports Q1 revenue growth, tackles pricing challenges

10x Genomics saw strong revenue growth in spatial but faced challenges with new Chromium technology orders.
The company aims to drive adoption by reducing prices and expanding the total market for single-cell technology.
Customers are showing interest in multiple platforms, setting up genomics infrastructure with various use cases.
Despite obstacles, 10x Genomics remains optimistic about the potential of its technology platforms and market growth.

10X Genomics reports Q3 revenue decline, focuses on growth strategies

10X Genomics faced revenue decline in Q3 due to sales restructuring and cautious customer spending, with full-year revenue expected to decline by 3%. Despite challenges, the company is focused on driving growth through new product launches, evolving commercial structure, and expanding access to single cell analysis. Confidence in the company's path forward remains strong, with expectations for sequential improvements and a focus on long-term opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q1 2021 Results - Earnings Call Transcript

Q1 2021 revenue growth of 47% over prior year Q1 2021 revenue growth of 47% over prior year

10x Genomics Reports First Quarter 2021 Financial Results

On Wednesday, May 05, 10x Genomics (NASDAQ:TXG) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

10x Genomics's Earnings: A Preview

PLEASANTON, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming BofA Securities 2021 Virtual Healthcare Conference.

10x Genomics to Present at the BofA Securities 2021 Virtual Healthcare Conference

How much potential does this company have?

What Investors Need to Know About 10x Genomics

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: 10x Genomics (TXG) Q1 Earnings Expected to Decline

Beam Therapeutics

Fate Therapeutics

3 Hot Healthcare Stocks Cathie Wood Is Buying in April

PLEASANTON, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the first quarter 2021 after market close on Wednesday, May 5th, 2021. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

10x Genomics to Report First Quarter Financial Results on May 5, 2021

The company's technology is helping researchers understand the genetic underpinnings of the disease.

How 10x Genomics Could Help Change How Parkinson's Disease Is Treated

The company's technology is enabling researchers to explore single cells like never before.

How 10x Genomics Is Turbocharging Genetic Research

The company's genomics technology was important in the research of these two diseases.

How 10x Genomics Helped Achieve Breakthroughs in Cystic Fibrosis and COVID

10x Genomics CEO Serge Saxonov thinks we're at the threshold of some big discoveries.

How Genomics Research Could Change How Multiple Sclerosis Is Treated

The company's CEO thinks it's capitalizing on the biggest value-creation opportunity of the next several decades.

Could 10x Genomics Deliver a 10x Return?

10x Genomics' CEO identifies three key things to look for.

How Can Investors Find Innovative Companies Early?

10x Genomics CEO: Why We're at the Beginning of a Biology Revolution

Why 10x Genomics' CEO Is Optimistic About the Battle Against COVID

Along with recent release of CellPlex, product increases access through affordability Along with recent release of CellPlex, product increases access through affordability

10x Genomics Puts Single Cell Analysis Within Reach of All With Low Throughput Gene Expression Kit

Eighteen months after going public, 10x Genomics Inc.'s (TGX) shares have tripled to more than $166, yet analysts think that's still well below its twelve-month median price target. Some on Wall Street feel the shares could go as high as $240.

Analysts See Plenty of Potential for 10x Genomics

ConocoPhillips

Pure Storage

Signet Jewelers

Axalta Coating Systems

Dow Inc

Jounce Therapeutics

1Life Healthcare

United States Steel

With the trading day nearing halfway over, the broad markets were trading sideways on Monday.

Conoco, Dow, Pure Storage, Signet Jewelers and More of Monday Afternoon's Analyst Calls

City to Change Street Name to ‘Genomics Place'

10x Genomics Expands Pleasanton Headquarters with New Facilities at Two Locations

CHICAGO--(BUSINESS WIRE)--OMX Ventures expands team with addition of Jamie Kasuboski, Ph.D. as Vice President and Kevin Ness, Ph.D. as Fund Advisor.

OMX Ventures Adds New Team Members to Expand Investment and Company Creation Activities in $150M Oversubscribed Fund I

PLEASANTON, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming 41st Annual Cowen Health Care Conference.

10x Genomics to Present at the 41st Annual Cowen Health Care Conference

Acquires Tetramer Shop; Reveals Details on Upcoming Products Acquires Tetramer Shop; Reveals Details on Upcoming Products

10x Genomics Showcases Next Wave of Innovations at First Ever Xperience Event

The problem was the company's worsening bottom line.

Why 10x Genomics' Soaring Q4 Revenue Wasn't Enough to Impress Investors

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q4 2020 Results - Earnings Call Transcript

News for 10X Genomics Stock (TXG)